Cargando…
PPARγ as a Potential Target to Treat Airway Mucus Hypersecretion in Chronic Airway Inflammatory Diseases
Airway mucus hypersecretion (AMH) is a key pathophysiological feature of chronic airway inflammatory diseases such as bronchial asthma, cystic fibrosis, and chronic obstructive pulmonary disease. AMH contributes to the pathogenesis of chronic airway inflammatory diseases, and it is associated with r...
Autores principales: | Shen, Yongchun, Chen, Lei, Wang, Tao, Wen, Fuqiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3385647/ https://www.ncbi.nlm.nih.gov/pubmed/22761606 http://dx.doi.org/10.1155/2012/256874 |
Ejemplares similares
-
Management of airway mucus hypersecretion in chronic airway inflammatory disease: Chinese expert consensus (English edition)
por: Shen, Yongchun, et al.
Publicado: (2018) -
Discovery of a drug to treat airway mucus hypersecretion
por: Dickey, Burton F., et al.
Publicado: (2022) -
Clinical significance of airway mucus hypersecretion in chronic obstructive pulmonary disease
por: Tian, Pan-wen, et al.
Publicado: (2015) -
Association of the CFTR gene with asthma and airway mucus hypersecretion
por: Crespo-Lessmann, Astrid, et al.
Publicado: (2021) -
Azithromycin Inhibits Mucus Hypersecretion from Airway Epithelial Cells
por: Shimizu, Takeshi, et al.
Publicado: (2012)